proaches consisting in chlorination of 6-methyluracil fol-
lowed by amination, nitration, reduction, and finally
cyclization of the intermediate 4,5-diamino-6-methylpy-
rimidine with orthoformate. In 1974, the coupling of
6-chloropurines with ylides from alkyltriphenylphospho-
nium halides offered9 the first straightforward method
for the synthesis of 6-alkylpurines. In the last two
decades, the development of cross-coupling reactions led
to general and efficient methodology for the synthesis of
6-alkylpurines.10 Thus, 6-methylpurine derivatives were
prepared by Pd-catalyzed cross-couplings of 6-chloropu-
rines with methylzinc bromide11 or trimethylaluminum.12
Other 6-alkylpurines were also prepared by Ni-13 or Cu-
catalyzed14 couplings of 6-halo- or 6-methylsulfanylpu-
rines with Grignard reagents. Very recently, Fe-catalyzed
cross-couplings of Grignard reagents with aryl halides
(including 6-chloropurines) have been described15 as an
efficient and general methodology.
This paper reports on the general synthesis of 2-sub-
stituted 6-methylpurines by regioselective cross-coupling
methylations of 2,6-dichloropurines. In the past, only
several compounds of this class have been prepared by
cyclization7,8 or by methylation of protected 2-methyl-6-
chloropurine ribonucleoside with a Wittig reagent.16 The
only example of regioselective methylation of 9-benzyl-
2,6-dichloropurine with methylzinc bromide leading to
9-benzyl-2-chloro-6-methylpurine was reported in a pre-
liminary communication17 without details. Our aim was
to study and compare the regioselectivity of methylation
of 2,6-dichloropurines with diverse methylorganometal
reagents and to develop a practical and general meth-
odology for the synthesis of 2-chloro-6-methylpurines as
well as of some 2-C-substituted 6-methylpurines ap-
plicable both to purine bases and nucleosides.
An Efficien t Syn th esis of 2-Su bstitu ted
6-Meth ylp u r in e Ba ses a n d Nu cleosid es by
F e- or P d -Ca ta lyzed Cr oss-Cou p lin g
Rea ction s of 2,6-Dich lor op u r in es
Michal Hocek*,† and Hana Dvorˇa´kova´‡
Institute of Organic Chemistry and Biochemistry,
Academy of Sciences of the Czech Republic, CZ-16610
Prague 6, Czech Republic. Central NMR Laboratory,
Prague Institute of Chemical Technology,
CZ-16628 Prague 6, Czech Republic
hocek@uochb.cas.cz
Received March 18, 2003
Abstr a ct: Fe-catalyzed cross-coupling reactions of 9-sub-
stituted or protected 2,6-dichloropurines with 1 equiv of
methylmagnesium chloride gave regioselectively 2-chloro-
6-methylpurines in good yields. The same reactions with 3
equiv of methylmagnesium chloride or Pd-catalyzed reac-
tions with trimethylaluminum afforded 2,6-dimethylpurines.
The 2-chloro-6-methylpurines underwent another coupling
with phenylboronic acid to give 6-methyl-2-phenylpurines.
All reactions were perfomed for Bn- and THP-protected
purine bases as well as for acyl-protected ribosides and
2-deoxyribosides. After deprotection, free purine bases and
nucleosides were obtained.
6-Methylpurine is highly cytotoxic.1 Its liberation from
the 2′-deoxyribonucleoside by purine nucleoside phos-
phorylases is used for detection of mycoplasma in cell
cultures.2 It is highly potent and toxic to nonproliferating
and proliferating tumor cells. Recently, the use of cyto-
toxic 6-methylpurine base liberated by purine nucleoside
phosphorylases from its nontoxic deoxyribonucleoside
was proposed as a novel principle in the gene therapy of
cancer.3 6-Methylpurines are also versatile starting
materials for further modifications of the methyl group
leading to 6-formyl-4 or 6-halomethylpurines,5 purine-6-
carboxamides,6 etc.
Cross-coupling reactions of 2,6- and 6,8-dihalopurines
are chemo- and regioselective.17,18 Thus, the reactions of
(9) Taylor, E. C.; Martin, S. F. J . Am. Chem. Soc. 1974, 96, 8095-
8102.
(10) Review: Hocek, M. Eur. J . Org. Chem. 2003, 245-254.
(11) (a) Gundersen, L.-L.; Bakkestuen, A. K.; Aasen, A. J .; Øveras,
H.; Rise, F. Tetrahedron 1994, 50, 9743-9756. (b) Hassan, A. E. A.;
Abou-Elkair, R. A. I.; Montgomery, J . A.; Secrist III, J . A. Nucleosides,
Nucleotides, Nucleic Acids 2000, 19, 1123-1134.
(12) Cˇ esnek, M.; Hocek, M.; Holy´, A. Collect. Czech. Chem. Commun.
2000, 65, 1357-1373.
(13) (a) Bergstrom, D. E.; Reddy, P. A. Tetrahedron Lett. 1982, 23,
4191-4194. (b) Sugimura, H.; Takei, H. Bull. Chem. Soc. J pn. 1985,
58, 664-666. (c) Estep, K. G.; J osef, K. A.; Bacon, E. R.; Carabates, P.
M.; Rumney, S., IV; Pilling, G. M.; Krafte, D. S.; Volberg, W. A.; Dillon,
K.; Dugrenier, N.; Briggs, G. M.; Canniff, P. C.; Gorczyca, W. P.;
Stankus, G. P.; Ezrin, A. M. J . Med. Chem. 1995, 38, 2582-2595.
(14) (a) Dvorˇa´kova´, H.; Dvorˇa´k, D.; Holy´, A. Tetrahedron Lett. 1996,
37, 1285-1288. (b) Dvorˇa´kova´, H.; Dvorˇa´k, D.; Holy´, A. Collect. Czech.
Chem. Commun. 1998, 63, 2065-2074.
(15) Fu¨rstner, A.; Leitner, A.; Mendez, M.; Krause, H. J . Am. Chem.
Soc. 2002, 124, 13856-13864.
(16) Christensen, L. F.; Cook, D. P.; Robins, R. K.; Meyer, R. B. J .
Carbohydr. Nucleosides Nucleotides 1977, 4, 175-188.
(17) Gundersen, L.-L.; Langli, G.; Rise, F. Tetrahedron Lett. 1995,
36, 1945-1948.
(18) (a) Langli, G.; Gundersen L.-L.; Rise. F. Tetrahedron 1996, 52,
5625-5638. (b) Nolsoe, J . M. J .; Gundersen, L.-L.; Rise, F. Acta Chem.
Scand. 1999, 53, 366-372. (c) Havelkova´, M.; Dvorˇa´k, D.; Hocek, M.
Synthesis 2001, 1704-1710. (d) Hocek M., Holy´ A., Dvorˇa´kova´ H.:
Collect. Czech. Chem. Commun. 2002, 67, 325-335. (e) Hocek, M.;
Votruba, I.; Dvorˇa´kova´, H. Tetrahedron 2003, 59, 607-611. (f) Hocek
M., Hockova´, D.; Sˇtambasky´, J . Collect. Czech. Chem. Commun. 2003,
68, 837-848.
Traditionally, the 6-methylpurine bases were pre-
pared7,8 by low-yielding multistep heterocyclization ap-
* To whom correspondence should be addressed. Fax: +420
233331271.
† Institute of Organic Chemistry and Biochemistry.
‡ Prague Institute of Chemical Technology.
(1) Montgomery, J . A.; Hewson, K. J . Med. Chem. 1968, 11, 48-52.
(2) (a) McGarrity, G. J .; Carson, D. A. Exp. Cell Res. 1982, 139, 199-
205. (b) Whitaker, A. M.; Windsor, G. D.; Burnett, C. M.; Taylor, C. H.
Dev. Biol. Stand. 1987, 66, 503-509. (c) Ishiguro, K.; Taira, S.; Sasaki,
T.; Nariuchi, H. J . Immunol. Methods. 1988, 108, 39-43.
(3) (a) Parker, W. B.; King, S. A.; Allan, P. W.; Bennett, L. L., J r.;
Secrist, J . A.; Montgomery, J . A.; Gilbert, K. S.; Waud, W. R.; Wells,
A. H.; Gillespie, G. Y.; Sorscher, E. J . Hum. Gene Ther. 1997, 8, 1637-
1644. (b) Parker, W. B.; Allan, P. W.; Shaddix, S. C.; Rose, L. M.;
Speegle, H. F.; Gillespie, G. Y.; Bennett, L. L., J r. Biochem. Pharmacol.
1998, 55, 1673-1681.
(4) Giner-Sorolla, A. Chem. Ber. 1968, 101, 611-618.
(5) Cohen, S.; Thom, E.; Bendich, A. J . Org. Chem. 1962, 27, 3545-
3549.
(6) Agranat, I.; Barak, A. Heterocycles 1978, 11, 213-218.
(7) (a) Gabriel, S.; Colman, J . Ber. Dtsch. Chem. Ges. 1901, 34,
1234-1257. (b) Prasad, R. N.; Noell, C. W.; Robins, R. K. J . Am. Chem.
Soc. 1959, 81, 193-197.
(8) Woenckhaus, C. W. Chem. Ber. 1964, 97, 2439-2446.
10.1021/jo034351i CCC: $25.00 © 2003 American Chemical Society
Published on Web 06/13/2003
J . Org. Chem. 2003, 68, 5773-5776
5773